PMVP pmvpharma.com: Enterprise Value to EBITDA Ratio

PMV Pharmaceuticals (PMVP) specializes in developing small molecules for the regeneration of defective p53 proteins in solid tumors. The successful implementation of these formulas guarantees long-term patent protection and a stable profit stream driven by consumer demand inertia. The company's production facilities are fully certified and operate without interruption. The price history on GURU.Markets based on the EV/EBITDA metric is 0.00, which complements the data from the current screening of target compounds.

PMVP (PMV Pharmaceuticals Inc.) Enterprise Value to Operating Income Before Depreciation Ratio history from 11/23/2025 to 11/12/2026

Comprehensive metric breakdowns and analytics for pmvpharma.com (PMVP)

- stock price and consensus target price:

Stock Quotes PMV Pharma|PMVP - Average Forecast Price

- company stock capitalization data:

Market Valuation PMV Pharmaceuticals, Inc|PMVP - Value Adjusted for Debt and Cash

- business book valuation details:

Accounting Value per Share PMV Pharmaceuticals|PMVP - Total Net Assets|Market Capitalization to Book Value Ratio pmvpharma.com|PMVP - Company Total Assets

- debt and solvency information:

- net income and valuation multiples indicators:

PMVP - Company Net Income|Projected Future Earnings PMV Pharmaceuticals|PMVP - Price to Earnings Multiple|Projected Price to Earnings PMV Pharmaceuticals|PMVP - Growth-Adjusted Payback Ratio|Enterprise Value to EBITDA Ratio PMV Pharmaceuticals, Inc|PMVP - Company profit before taxes, interest and amortization|Net earnings per share (EPS TTM) PMV Pharmaceuticals|PMVP - Earnings per share for the trailing year|Quarterly EPS earnings growth pmvpharma.com|PMVP - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year PMV Pharmaceuticals

Basic company analysis:PMV Pharma PMVP

Amid extreme competition for leadership in p53 mutation therapy, this indicator allows for an assessment of PMV Pharmaceuticals (PMVP) resilience to market risks through the lens of debt load. By analyzing the company's trend EV/EBITDA level, an investor compares the total enterprise value with operating profit before depreciation and amortization, determining the asset's real value relative to its ability to generate cash flow.

Competitor analysis

Genmab US - Enterprise Value to EBITDA Ratio|Exelixis Inc. (EXEL) - Company Value to EBITDA|NUVL: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation KYMR (kymeratx.com)|IDYA (IDEAYA Biosciences, Inc.) - Enterprise Value to EBITDA Ratio|ELVN: Enterprise Value to Operating Income Before Depreciation Ratio|ORIC (ORIC Pharma) - EV/EBITDA Multiple|EV/EBITDA Multiple Relay Corp|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Nurix Therapeutics (NRIX)|TYRA (tyra.bio) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple VSTM (Verastem)|Enterprise Value to EBITDA Multiple Monte Rosa Therapeutics Inc|Cullinan Therapeutics Inc - EV/EBITDA Multiple|Company Value to EBITDA Immuneering Corp.|CCCC (C4 Therapeutics, Inc.) - Enterprise Value to EBITDA Ratio|BDTX: Enterprise Value to Operating Income Before Depreciation Ratio|RPTX (Repare Therapeutics Inc.) - EV/EBITDA Multiple|Company Value to EBITDA Karyopharm KPTI|EV/EBITDA Multiple PPCB|Cyclacel - Enterprise Value to Operating Income Before Depreciation|Aadi Bioscience, Inc. - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation ALRN|BPMC: Enterprise Value to EBITDA Ratio|GlycoMimetics, Inc. - Enterprise Value to Operating Income Before Depreciation Ratio|SWTX: EV/EBITDA Multiple